Flatiron Health

Flatiron Health
Name	Flatiron Health
Industry	Biotechnology, Health IT
Founded	2012
Founders	Nat Turner; Zach Weinberg
Headquarters	New York City, New York, United States
Key people	Nat Turner; Zach Weinberg; Carolyn Fisher
Products	OncoEMR; OncoAnalytics; Real‑World Evidence services
Parent	Roche (majority investor)

Flatiron Health. Flatiron Health is a private oncology-focused health technology company that develops electronic health record and data analytics products for cancer care and research. The company was founded in 2012 by entrepreneurs who previously launched a consumer technology startup and later attracted investment from biopharmaceutical and technology firms, culminating in a strategic transaction with a multinational diagnostics and pharmaceuticals company. Flatiron operates at the nexus of clinical oncology operations, health informatics, and biopharma research, providing data platforms and services intended to accelerate oncology drug development and improve treatment delivery.

History

Flatiron Health was founded in 2012 by Nat Turner and Zach Weinberg after earlier entrepreneurship in the consumer technology sector and subsequent immersion in oncology care settings such as the Memorial Sloan Kettering Cancer Center, Dana‑Farber Cancer Institute, and Mount Sinai. Early collaborators and advisors included clinicians and informaticians affiliated with institutions like Johns Hopkins University, Massachusetts General Hospital, and the University of California, San Francisco. The firm secured venture capital from investors including Google Ventures, OrbiMed Advisors, and New Enterprise Associates, and later engaged in corporate investment and a majority acquisition by Roche, a global company headquartered in Basel known for diagnostics and pharmaceuticals. Key milestones include product launches, expansion of the network of community oncology practices, agreements with major biopharmaceutical firms, and public attention through coverage in The New York Times, The Wall Street Journal, and industry outlets.

Technology and Products

Flatiron developed oncology‑specific electronic health record tools and a suite of analytics products designed to extract clinically relevant data from structured and unstructured sources. The company's offerings include practice management and oncology EHR systems used in community practices, alongside data curation pipelines that leverage natural language processing techniques and human abstractors trained to interpret pathology reports, radiology notes, and clinician documentation, with workflows informed by standards from the College of American Pathologists and National Comprehensive Cancer Network. The platform integrates data elements such as staging from American Joint Committee on Cancer, biomarker results from CLIA‑certified laboratories, and therapy regimens mapped to Anatomical Therapeutic Chemical classification. Products have been positioned against competing systems from vendors like Epic Systems, Cerner, and GE Healthcare, and have been cited in technology analyses published by organizations including HIMSS and MIT Technology Review.

Clinical Research and Real-World Evidence

The company has cultivated a large de‑identified oncology dataset used to generate real‑world evidence for regulatory and clinical decision support purposes. Collaborations have involved biopharmaceutical companies such as Pfizer, Bristol‑Myers Squibb, Merck, and Novartis for retrospective analyses, external control arms, and post‑marketing safety studies submitted to regulatory agencies like the U.S. Food and Drug Administration and the European Medicines Agency. The dataset has supported peer‑reviewed publications in journals including The New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology, and has been used in projects with academic centers like Stanford University, Harvard Medical School, and Yale School of Medicine. Methodological debates have referenced frameworks from the International Society for Pharmacoepidemiology and standards such as those promoted by the Observational Medical Outcomes Partnership.

Business Model and Partnerships

Flatiron’s revenue model combines software licensing for clinical practice tools, professional services for data curation and analytics, and research collaborations with biopharmaceutical companies and contract research organizations like IQVIA. Strategic partnerships have included alliances with diagnostic companies, payer networks, and academic research consortia such as ASCO’s TAPUR program and NCI‑funded initiatives. The company engaged in commercial agreements and data licensing arrangements with sponsors of oncology clinical trials, and its corporate trajectory included investment and a majority acquisition by Roche, alongside continued partnerships with venture investors and strategic collaborators like Google Ventures and OrbiMed.

Regulation, Privacy, and Ethics

Operations intersect with regulatory regimes and privacy frameworks including HIPAA in the United States and data protection rules relevant to multinational research collaborations. De‑identification approaches, patient consent models, and data governance policies have been discussed in the context of guidance from the Office for Human Research Protections, the European Union regulatory environment, and institutional review boards at academic partners. Ethical debates have involved patient privacy advocates, bioethicists at institutions such as the Hastings Center, and policy analysts from think tanks who examined issues of consent, data ownership, and the use of real‑world data in regulatory decision making.

Reception and Impact

Flatiron has been recognized for accelerating access to longitudinal oncology data, contributing to pragmatic trial design, and enabling external control arm methodologies cited by regulators and industry. Coverage in outlets including The New York Times, The Wall Street Journal, Nature, and STAT has highlighted both innovation and controversies around commercial uses of clinical data. Academic citations and policy discussions have compared Flatiron’s dataset to registries such as SEER and administrative databases maintained by Centers for Medicare & Medicaid Services, noting strengths in clinical detail and limitations related to representativeness and missingness. Industry awards and conference presentations at venues like ASCO Annual Meeting and BIO International Convention have signaled influence across oncology research, clinical practice, and pharmaceutical development.

Category:Health care companies Category:Companies based in New York City Category:Biotechnology companies